EGFR and lung carcinoma: In addition, clinical studies have identified combinational therapies of metformin and antineoplastic agents [traditional chemotherapy drugs, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), or immune checkpoint inhibitors (ICIs)] in lung cancer, both in diabetic and non-diabetic subjects.